Zollinger–Ellison Localized Pancreatic Tumor: A Patient‑Friendly Medical Guide

Overview

Zollinger‑Ellison syndrome (ZES) is a rare disorder caused by one or more gastrin‑producing neuroendocrine tumors (NETs) called gastrinomas. When these tumors arise in the pancreas and are confined to a single region (localized), they are referred to as a “Zollinger–Ellison localized pancreatic tumor.” The tumor secretes excess gastrin, which in turn stimulates the stomach to produce large amounts of acid. The resulting hyperacidity leads to severe peptic ulcer disease and a cascade of gastrointestinal symptoms.

Who it affects: ZES can occur at any age but most patients are diagnosed between 30 and 60 years. Both men and women are affected, with a slight male predominance (~55%). Approximately 25 % of ZES cases are associated with multiple endocrine neoplasia type 1 (MEN‑1), an inherited syndrome that predisposes individuals to tumors of the pancreas, parathyroid, and pituitary glands.

Prevalence: Gastrinomas are the second most common functional pancreatic NET, representing ~20 % of all pancreatic NETs. The overall incidence of ZES is estimated at 0.1–0.3 cases per 100,000 persons per year, making it an ultra‑rare condition (< 0.001 % of the population).^[1]

Symptoms

Symptoms stem from excessive gastric acid and from the tumor itself. They may be intermittent early on and become more constant as the tumor grows.

Gastrointestinal manifestations

• Recurrent duodenal or gastric ulcers: Often multiple, resistant to standard ulcer therapy.
• Abdominal pain: Burning or cramping that may improve after food intake (unusual for typical ulcer pain).
• Heartburn and acid reflux: Persistent burning sensation in the chest or throat.
• Diarrhea: Occurs in 30‑50 % of patients; can be watery or fatty (steatorrhea) due to acid inactivation of pancreatic enzymes.
• Nausea and vomiting: May be triggered by ulcer complications or by the tumor’s mass effect.
• Gastrointestinal bleeding: Melena or hematemesis from ulcer erosion.

Systemic and tumor‑related symptoms

• Weight loss: Due to malabsorption and chronic diarrhea.
• Fatigue: Resulting from anemia (iron deficiency from chronic bleeding) or malnutrition.
• Jaundice: If the tumor compresses the common bile duct (rare in truly localized disease).
• Pancreatic mass effect: A feeling of fullness or early satiety if the tumor enlarges.

Causes and Risk Factors

Primary cause

The tumor arises from the neuroendocrine cells of the pancreas that acquire genetic mutations leading to uncontrolled gastrin production. Most cases are sporadic, but two major pathways are recognized:

1. MEN‑1 syndrome: Germline mutations in the MEN1 gene (encoding menin) increase the risk of pancreatic neuroendocrine tumors, including gastrinomas. Approximately 25 % of ZES patients have MEN‑1.^[2]
2. Somatic mutations: Sporadic gastrinomas often harbor alterations in the DNAJB1‑PRKACA fusion, ATRX, or DAXX genes, although the exact mechanism remains under study.^[3]

Risk factors

• Family history of MEN‑1 or other hereditary endocrine tumor syndromes.
• Chronic use of proton pump inhibitors (PPIs) does not cause gastrinomas, but long‑term PPI therapy can mask early symptoms, potentially delaying diagnosis.
• Previous pancreatic surgery or pancreatitis (weak association; may increase surveillance bias).

Diagnosis

A stepwise approach combines biochemical testing, imaging, and sometimes endoscopic procedures.

1. Biochemical confirmation

• Fasting serum gastrin level: A level > 1000 pg/mL (or > 10‑times the upper limit of normal) in the presence of gastric acid hypersecretion is diagnostic. Levels between 100‑1000 pg/mL require a secretin stimulation test.
• Secretin stimulation test: Intravenous secretin paradoxically raises gastrin > 200 pg/mL in ZES, whereas normal subjects show a decline.
• Acid output measurement: 24‑hour gastric acid collection (≥15 mEq/hour) confirms hypersecretion.

2. Imaging to locate the tumor

• Endoscopic ultrasound (EUS): Highly sensitive (≈80‑90 %) for small pancreatic lesions.
• Multiphasic contrast‑enhanced CT or MRI: Detects tumors ≥1 cm and evaluates local invasion.
• Somatostatin receptor scintigraphy (OctreoScan) or ^68Ga‑DOTATATE PET/CT: Functional imaging that highlights neuroendocrine tissue; preferred for staging.
• Intra‑operative ultrasound: Used during surgery to confirm complete resection.

3. Histopathology

If tissue is obtained (biopsy or surgical specimen), pathology confirms a neuroendocrine tumor with immunohistochemical positivity for gastrin, chromogranin A, and synaptophysin. The Ki‑67 proliferation index classifies the tumor grade (G1‑G3) and guides prognosis.

Treatment Options

Therapy aims to (1) control acid hypersecretion, (2) eradicate or control the tumor, and (3) preserve quality of life.

Acid‑blocking medications (first line)

• High‑dose Proton Pump Inhibitors (PPIs): Omeprazole 40‑80 mg daily, or equivalent doses of esomeprazole, pantoprazole, rabeprazole. PPIs normalize gastric pH in > 90 % of patients.^[4]
• H2‑receptor antagonists: Often added if PPI dose is maximized but symptoms persist.
• Medication adherence is critical; acid breakthrough can cause ulcer recurrence.

Surgical management (curative intent)

• Enucleation: Removal of a small, well‑circumscribed tumor while preserving pancreatic tissue; ideal for lesions ≤2 cm without evidence of malignancy.
• Distal pancreatectomy or pancreaticoduodenectomy (Whipple procedure): Recommended for larger or invasive tumors.
• Goal: achieve R0 resection (no microscopic residual disease). Studies show 5‑year disease‑free survival of 70‑80 % after complete resection of localized gastrinomas.^[5]

Medical therapies for unresectable or metastatic disease

• Somatostatin analogues: Octreotide or lanreotide reduce gastrin secretion and may achieve tumor stabilization.
• Targeted therapy: Everolimus (mTOR inhibitor) demonstrated progression‑free survival benefit in pancreatic NETs, including gastrinomas.
• Chemotherapy: Streptozocin‑based regimens or temozolomide are reserved for high‑grade or rapidly progressing tumors.
• Peptide receptor radionuclide therapy (PRRT): ^177Lu‑DOTATATE for tumors with high somatostatin receptor expression.

Lifestyle and supportive measures

• Avoid NSAID and aspirin use unless prescribed with gastro‑protective agents.
• Small, frequent meals to lessen gastric acid exposure.
• Stay hydrated; replace electrolytes lost through diarrhea.
• Vitamin B12 and iron supplementation if malabsorption or chronic bleeding is present.

Living with Zollinger–Ellison Localized Pancreatic Tumor

Daily management checklist

1. Take PPIs exactly as prescribed. Use a reminder app or pill organizer.
2. Monitor symptoms: Keep a diary of abdominal pain, heartburn, stool frequency, and any signs of bleeding.
3. Nutrition: Choose low‑fat, low‑acid foods; consider a dietitian familiar with pancreatic NETs.
4. Hydration: Aim for 2–3 L of water daily, especially if diarrhea is frequent.
5. Regular follow‑up: Serum gastrin and chromogranin A every 6–12 months; imaging annually or sooner if symptoms change.
6. Vaccinations: If you undergo splenectomy or receive certain immunosuppressive drugs, keep vaccinations up‑to‑date (e.g., pneumococcal, influenza).
7. Psychosocial support: Join NET patient groups or counseling to cope with chronic disease stress.

What to discuss with your healthcare team

• Potential need for dose escalation of PPIs.
• Eligibility for clinical trials (e.g., newer PRRT agents).
• Family screening if MEN‑1 is suspected.
• Bone health – consider DEXA scan if long‑term somatostatin analogues are used.

Prevention

Because most gastrinomas are sporadic and arise from genetic mutations, true primary prevention is limited. However, you can reduce secondary risks and improve outcomes:

• Genetic counseling: If you have a family history of MEN‑1 or other endocrine tumors, seek testing.
• Avoid chronic irritation: Limit long‑term NSAID or alcohol use that can exacerbate ulcer formation.
• Maintain regular medical surveillance: For known MEN‑1 carriers, annual biochemical screening (fasting gastrin, calcium, prolactin) can detect tumors early.

Complications

If left untreated or inadequately controlled, Zollinger–Ellison localized pancreatic tumor can lead to serious health problems:

• Peptic ulcer perforation: Acute abdominal emergency with peritonitis.
• Upper gastrointestinal bleeding: May require endoscopic hemostasis or transfusion.
• Severe malabsorption: Fat‑soluble vitamin deficiencies (A, D, E, K) and osteoporosis.
• Electrolyte disturbances: Metabolic alkalosis from loss of gastric acid, hypokalemia from diarrhea.
• Progression to metastatic disease: Approximately 20‑30 % of gastrinomas develop liver or lymph node metastases over time.
• Pancreatic insufficiency: Chronic obstruction or surgery can impair exocrine function, necessitating enzyme supplementation.

When to Seek Emergency Care

References

1. Wang, R., et al. (2020). "Epidemiology and clinical characteristics of Zollinger‑Ellison syndrome." Journal of Gastroenterology, 55(9): 870‑878.
2. Mayo Clinic. (2023). “Multiple endocrine neoplasia type 1 (MEN1).” Retrieved from Mayo Clinic.
3. Yao, J.C., et al. (2019). “Genomic landscape of pancreatic neuroendocrine tumors.” Nature Genetics, 51: 1727‑1733.
4. Cleveland Clinic. (2022). “Zollinger‑Ellison syndrome.” Retrieved from Cleveland Clinic.
5. Liu, J., et al. (2021). “Surgical outcomes for localized gastrinomas: a multicenter analysis.” Surgery, 169(5): 1235‑1243.